Analyst Price Targets — BIIB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 25, 2026 10:26 am | — | RBC Capital | $260.00 | $218.12 | TheFly | Biogen price target raised to $260 from $240 at RBC Capital |
| August 13, 2026 9:40 am | — | Wolfe Research | $300.00 | $208.87 | TheFly | Biogen upgraded to Outperform from Peer Perform at Wolfe Research |
| July 30, 2026 4:06 pm | Terence Flynn | Morgan Stanley | $231.00 | $206.50 | TheFly | Biogen price target raised to $231 from $222 at Morgan Stanley |
| July 30, 2026 2:16 pm | — | H.C. Wainwright | $251.00 | $205.74 | TheFly | Biogen price target raised to $251 from $237 at H.C. Wainwright |
| July 30, 2026 1:46 pm | — | RBC Capital | $240.00 | $204.10 | TheFly | Biogen price target lowered to $240 from $242 at RBC Capital |
| July 30, 2026 1:16 pm | — | UBS | $240.00 | $204.62 | TheFly | Biogen price target raised to $240 from $225 at UBS |
| July 30, 2026 11:04 am | — | Canaccord Genuity | $248.00 | $209.23 | TheFly | Biogen price target raised to $248 from $245 at Canaccord |
| July 29, 2026 5:51 pm | Jay Olson | Oppenheimer | $300.00 | $209.23 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Biogen (BIIB) |
| July 21, 2026 12:01 pm | Yatin Suneja | Guggenheim | $280.00 | $203.03 | TheFly | Biogen price target raised to $280 from $260 at Guggenheim |
| July 13, 2026 12:03 pm | — | Wedbush | $201.00 | $202.05 | TheFly | Biogen price target raised to $201 from $196 at Wedbush |
Latest News for BIIB
–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–
TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
Canada Pension Plan Investment Board purchased a new position in shares of Biogen Inc. (NASDAQ: BIIB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,602 shares of the biotechnology company's stock, valued at approximately $2,939,000. Several other hedge funds and other
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.